Oncological Surgery Practice Questions

Q: What is the most common site for metastasis from carcinoma of the cheek?

Regional lymph nodes. **Explanation:** **1. Why Regional Lymph Nodes is Correct:** Carcinoma of the cheek (most commonly **Squamous Cell Carcinoma**) primarily spreads via the **lymphatic route**. In head and neck cancers, regional lymph node involvement is the most significant prognostic factor and the most common site of initial metastasis. Specifically, for the cheek (buccal mucosa), the primary drainage is to the **Submandibular (Level IB)** and **Upper Deep Cervical (Level II)** lymph nodes. Because the oral cavity is rich in lymphatic plexuses, early micrometastasis to these nodes is frequent, often occurring before any distant hematogenous spread. **2. Why the Other Options are Incorrect:** * **Lung (C):** While the lung is the most common site for *distant* (hematogenous) metastasis in head and neck cancers, it occurs much less frequently and usually much later in the disease progression compared to regional nodal spread. * **Liver (D) & Brain (A):** These are rare sites for metastasis from oral cavity cancers. They typically only occur in advanced, terminal stages of the disease after the cancer has already spread to the lungs. **3. Clinical Pearls for NEET-PG:** * **Most common site of oral cancer in India:** Buccal mucosa (often associated with betel nut/tobacco chewing, known as the "Indian Oral Carcinoma"). * **Staging:** The presence of a single positive regional lymph node (N1) significantly decreases the 5-year survival rate by nearly 50%. * **Skip Metastasis:** Occasionally, buccal carcinoma can skip Level I and present directly in Level II nodes. * **Distant Metastasis:** If a question specifically asks for the most common site of **distant** metastasis, the answer is **Lung**. If it asks for the most common site of **overall** metastasis, the answer is **Regional Lymph Nodes**.

Q: What is the primary treatment for Medullary Carcinoma of the thyroid?

Surgery only. **Explanation:** **Medullary Thyroid Carcinoma (MTC)** arises from the **parafollicular C-cells**, which are neuroendocrine in origin. Unlike follicular cells, C-cells do not concentrate iodine, making MTC fundamentally different from papillary or follicular thyroid cancers. **Why "Surgery Only" is correct:** The primary and only curative treatment for MTC is **Total Thyroidectomy with Central Compartment Neck Dissection (Level VI)**. Because MTC is highly resistant to both radiotherapy and chemotherapy, and does not respond to radioiodine, surgical clearance of the primary tumor and involved lymph nodes is the mainstay of management. **Why other options are incorrect:** * **Radiotherapy and Chemotherapy (A & B):** MTC is notoriously **radioresistant** and **chemoresistant**. These modalities are reserved only for palliative care in advanced, metastatic, or unresectable disease and are never the primary treatment. * **Radioiodine Ablation (D):** Since C-cells do not express the sodium-iodide symporter (NIS), they **do not take up Iodine-131**. Therefore, radioiodine therapy has no role in the management of MTC. **High-Yield Clinical Pearls for NEET-PG:** 1. **Tumor Marker:** Serum **Calcitonin** (used for diagnosis and monitoring recurrence) and CEA. 2. **Genetics:** 25% are familial (MEN 2A/2B syndromes) due to **RET proto-oncogene** mutations. Prophylactic thyroidectomy is indicated in carriers. 3. **Pre-op Screening:** Always rule out **Pheochromocytoma** (by checking urinary metanephrines) before surgery to avoid a hypertensive crisis. 4. **Amyloid Staining:** Histology shows nests of cells with **Congo Red-positive** amyloid stroma.

Q: A 50-year-old male patient presented with progressive dysphagia for 4 months, more pronounced for solids than liquids. He also reported significant weight loss, loss of appetite, odynophagia, a hoarse voice, and cervical lymphadenopathy. Upper GI endoscopy and barium studies were performed, and a biopsy of the lesion was sent for HPE. All of the following are risk factors for the suspected condition, except:

Barrett's esophagus. ### Explanation The clinical presentation—progressive dysphagia (solids > liquids), weight loss, hoarse voice (suggesting recurrent laryngeal nerve involvement), and cervical lymphadenopathy—strongly points toward **Squamous Cell Carcinoma (SCC)** of the esophagus, typically involving the upper or middle third. **1. Why Barrett’s Esophagus is the Correct Answer:** Barrett’s esophagus is a metaplastic change (stratified squamous to columnar epithelium) resulting from chronic GERD. It is the primary precursor for **Adenocarcinoma**, not Squamous Cell Carcinoma. Since the clinical features (hoarseness and cervical nodes) suggest a proximal/mid-esophageal lesion, SCC is the diagnosis, making Barrett’s the "except" option. **2. Analysis of Incorrect Options (Risk Factors for SCC):** * **Smoking:** A major risk factor for SCC. Tobacco contains nitrosamines that are directly carcinogenic to the esophageal squamous lining. * **Plummer-Vinson Syndrome:** Characterized by the triad of iron-deficiency anemia, esophageal webs, and glossitis. It carries a high risk of developing SCC in the post-cricoid region. * **Achalasia Cardia:** Chronic stasis of food leads to esophagitis and mucosal irritation, increasing the risk of SCC (usually after 15–20 years of disease). **3. NEET-PG High-Yield Pearls:** * **Most common site:** Worldwide, SCC is most common in the **middle third**; Adenocarcinoma is most common in the **lower third**. * **Most common histological type:** Globally, SCC is most common; however, in Western countries, Adenocarcinoma is rising. * **Tylosis (Palmar-plantar keratoderma):** An autosomal dominant condition with nearly 100% lifetime risk of esophageal SCC. * **Investigation of choice:** Upper GI Endoscopy + Biopsy. * **Staging:** EUS (Endoscopic Ultrasound) is best for T and N staging; PET-CT is best for distant metastasis (M).

Q: What is the standard treatment for Hodgkin's disease of the stomach?

None of the above. ### Explanation The management of primary gastric lymphoma has shifted dramatically from surgical to medical intervention. The correct answer is **None of the above** because the standard of care for Hodgkin’s disease (and most Non-Hodgkin Lymphomas) of the stomach is now **Chemotherapy and/or Radiotherapy**, without routine surgical resection. **1. Why "None of the above" is correct:** Historically, surgery was performed to prevent complications like perforation or bleeding. However, modern clinical trials have proven that Hodgkin’s disease is highly radiosensitive and chemosensitive. The current gold standard is systemic chemotherapy (e.g., ABVD regimen) with or without involved-site radiation. Surgery is reserved only for life-threatening complications (refractory bleeding or perforation). **2. Why the other options are incorrect:** * **Option A & B (Gastric Resection):** Routine resection is no longer recommended. It does not improve survival compared to medical therapy alone and carries significant morbidity (post-gastrectomy syndrome, nutritional deficiencies). * **Option C (Purely medical treatment):** While medical treatment is the mainstay, the term "purely" is often considered absolute in medical exams. Furthermore, the standard management of gastric lymphoma often involves a multidisciplinary approach including staging laparotomy (historically) or specific imaging/endoscopy protocols. **Clinical Pearls for NEET-PG:** * **Most common site** of extranodal lymphoma is the **Stomach**. * **Most common type** of gastric lymphoma is **MALToma** (associated with *H. pylori*) or **DLBCL**. * **Hodgkin’s Disease** of the stomach is extremely rare compared to Non-Hodgkin Lymphoma. * **Treatment of MALToma:** Triple therapy for *H. pylori* eradication is the first-line treatment for low-grade MALT lymphoma. * **Surgery's Role:** Currently limited to "Salvage Surgery" for complications.

Q: A 50-year-old lady presents with a thyroid swelling diagnosed as papillary carcinoma. The mass measures 4 cm at its greatest diameter and invades strap muscles. Lymph node status is negative. What is the stage of the disease?

Stage I. ### **Explanation** The staging of **Differentiated Thyroid Carcinoma (DTC)**, which includes Papillary and Follicular types, is unique because it is heavily dependent on the **age of the patient** at the time of diagnosis. According to the **AJCC 8th Edition** TNM staging system: **1. Why Stage I is Correct:** For patients **younger than 55 years**, the staging is simplified into only two categories: * **Stage I:** Any T, Any N, **M0** (No distant metastasis). * **Stage II:** Any T, Any N, **M1** (Distant metastasis present). In this case, the patient is **50 years old** (under the 55-year cutoff). Although the tumor is 4 cm and invades strap muscles (T3b), and regardless of the lymph node status (N0), the absence of distant metastasis (M0) automatically classifies this as **Stage I**. **2. Why Other Options are Incorrect:** * **Stage II:** In patients <55 years, this is reserved only for cases with distant metastasis (e.g., lung or bone spread). In patients ≥55 years, Stage II involves T1/T2 with N1 or T3 tumors. * **Stage III & IV:** These stages **do not exist** for patients under the age of 55 in the AJCC 8th edition. They are only applicable to patients ≥55 years with advanced local invasion (T4) or distant metastasis. **3. NEET-PG High-Yield Pearls:** * **Age Cutoff:** The AJCC 8th edition increased the prognostic age cutoff from **45 to 55 years**. * **T3b Definition:** Invasion of **strap muscles only** (sternohyoid, sternothyroid, thyrohyoid, or omohyoid) is classified as T3b. * **Prognosis:** Papillary carcinoma has an excellent prognosis; patients <55 years have a near 0% 10-year mortality rate if they are M0. * **Anaplastic Carcinoma:** Always remember that Anaplastic thyroid cancer is considered **Stage IV** regardless of age or size at presentation.

Q: A patient with oral cancer has an ipsilateral lymph node measuring 2 cm, single in number with capsular spread. According to TNM staging, what is this classified as?

N3. ### Explanation The correct answer is **N3** (specifically **N3a** or **N3b** depending on the presence of Extranodal Extension). #### 1. Why N3 is Correct According to the **AJCC 8th Edition** for Oral Cavity Cancers, the staging of cervical lymph nodes has been updated to include **Extranodal Extension (ENE)**, also known as capsular spread. * **Clinical N3b:** Defined as a single or multiple nodes with **clinically positive ENE**. * **Pathological N3b:** Defined as a single or multiple nodes with **pathologically proven ENE**. Even though the node is single and only 2 cm (which would traditionally be N1), the presence of **capsular spread (ENE)** automatically upgrades the stage to **N3b**. ENE is a significant prognostic factor indicating a higher risk of regional recurrence and distant metastasis. #### 2. Why Other Options are Wrong * **Nx:** This is used when regional lymph nodes cannot be assessed. In this case, the node has been measured and evaluated. * **N1:** This is a single ipsilateral node $\leq$ 3 cm **without** extranodal extension. * **N2:** This category includes nodes between 3–6 cm, or multiple nodes, but specifically **without** extranodal extension. #### 3. High-Yield Clinical Pearls for NEET-PG * **ENE Definition:** Extension of tumor through the lymph node capsule into the surrounding connective tissue. * **AJCC 7th vs 8th Edition:** The most critical change in the 8th edition for Head and Neck cancers is the incorporation of **ENE** into N-staging and **Depth of Invasion (DOI)** into T-staging. * **N3a:** A node > 6 cm without ENE. * **N3b:** Any node (regardless of size or number) with ENE. * **Management:** The presence of ENE is an absolute indication for **adjuvant chemoradiotherapy** post-surgery.

Q: The prognosis of rhabdomyosarcoma is likely to be poor if the site of the tumor is?

Extremity. **Explanation:** The prognosis of Rhabdomyosarcoma (RMS) is heavily influenced by the primary site of the tumor, which is a key component of the **Intergroup Rhabdomyosarcoma Study (IRS) Grouping System**. **Why Extremity is the Correct Answer:** Tumors located in the **extremities** are classified as **unfavorable sites**. These lesions are often associated with the **Alveolar histological subtype** (which carries a worse prognosis than the Embryonal type) and have a higher propensity for early lymphatic and hematogenous metastasis. Additionally, achieving wide surgical margins in the limbs can be challenging without significant functional loss. **Analysis of Incorrect Options:** * **Orbit (A):** This is considered a **favorable site**. Although it lacks a lymphatic supply (making nodal spread rare), tumors here present early due to proptosis, leading to early diagnosis and excellent cure rates. * **Paratesticular (B):** This is a **favorable site**. These are usually of the Embryonal subtype and are typically detected early as a painless scrotal mass. * **Urinary Bladder (D):** While the bladder/prostate region is generally considered "unfavorable" compared to the orbit, the **extremity** consistently carries a poorer prognosis in clinical staging systems. **High-Yield Clinical Pearls for NEET-PG:** * **Most common soft tissue sarcoma in children:** Rhabdomyosarcoma. * **Favorable Sites:** Orbit, Non-parameningeal Head & Neck, Genitourinary (excluding bladder/prostate), and Biliary tract. * **Unfavorable Sites:** Extremities, Bladder, Prostate, and Parameningeal areas (e.g., nasopharynx, middle ear). * **Histology:** **Embryonal** is the most common and has a better prognosis; **Alveolar** is more common in extremities and has a worse prognosis. * **Genetic Marker:** Alveolar RMS is associated with **t(2;13)** or **t(1;13)** translocations involving the *PAX-FOXO1* gene fusion.

Question 1

What is the most common site for metastasis from carcinoma of the cheek?

Accepted Answer

Regional lymph nodes

Answer

Brain

Answer

Lung

Answer

Liver

Question 2

Which of the following is NOT a risk factor for gallbladder cancer?

Accepted Answer

Adenomyosis

Answer

Absence of bile duct stones

Answer

Gallstones

Answer

Adenomatous polyps

Question 3

Osseous metastasis is most common if the primary tumor is in which organ?

Accepted Answer

Bronchus

Answer

Colon

Answer

Pancreas

Answer

Adrenal

Question 4

What is the most important prognostic factor for cancer of the esophagus?

Accepted Answer

Depth of tumor involvement

Answer

Length of tumor growth

Answer

Histological grade of the tumor

Answer

Immunohistochemical markers

Question 5

What is the primary treatment for Medullary Carcinoma of the thyroid?

Accepted Answer

Surgery only

Answer

Surgery and radiotherapy

Answer

Radiotherapy and chemotherapy

Answer

Radioiodine ablation

Question 6

A 50-year-old male patient presented with progressive dysphagia for 4 months, more pronounced for solids than liquids. He also reported significant weight loss, loss of appetite, odynophagia, a hoarse voice, and cervical lymphadenopathy. Upper GI endoscopy and barium studies were performed, and a biopsy of the lesion was sent for HPE. All of the following are risk factors for the suspected condition, except:

Accepted Answer

Barrett's esophagus

Answer

Smoking

Answer

Plummer-Vinson syndrome

Answer

Achalasia cardia

Question 7

What is the standard treatment for Hodgkin's disease of the stomach?

Accepted Answer

None of the above

Answer

Gastric resection

Answer

Gastric resection and chemotherapy

Answer

Purely medical treatment

Question 8

A 50-year-old lady presents with a thyroid swelling diagnosed as papillary carcinoma. The mass measures 4 cm at its greatest diameter and invades strap muscles. Lymph node status is negative. What is the stage of the disease?

Accepted Answer

Stage I

Answer

Stage II

Answer

Stage III

Answer

Stage IV

Question 9

A patient with oral cancer has an ipsilateral lymph node measuring 2 cm, single in number with capsular spread. According to TNM staging, what is this classified as?

Accepted Answer

N3

Answer

Nx

Answer

N1

Answer

N2

Question 10

The prognosis of rhabdomyosarcoma is likely to be poor if the site of the tumor is?

Accepted Answer

Extremity

Answer

Orbit

Answer

Paratesticular

Answer

Urinary bladder

Oncological Surgery — MCQs

Oncological Surgery — MCQs

On this page

Practice by Chapter

Want unlimited practice?